BOSTON--(BUSINESS WIRE)--MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced the company will present clinical data and results from two studies at the San Antonio Breast Cancer Symposium (SABCS), taking place December 6-10, 2016 at the Henry B. Gonzalez Convention Center in San Antonio, TX.
“We are pleased to have two of our studies involving MetaSite Breast™ accepted for presentation at this year’s San Antonio Breast Cancer Symposium, including an oral presentation by Dr. Joseph Sparano, principal investigator for the ECOG 2197 study,” stated Douglas A. Hamilton, CEO and President of MetaStat, Inc.
Presentations of MetaSite Breast™ studies in patients with Early Stage Breast Cancer (ESBC) include:
- Nested case-control study (n=481, 259 case-controlled pairs) of MetaSite Breast™ within a cohort of 3,760 patients diagnosed with ESBC from the Kaiser Permanente Northwest Health Care system;
- Prospectively designed retrospective study (n=600) in an independent cohort (E2197; NCT00003519) of ESBC patients treated with surgery, 4 cycles of adjuvant chemotherapy (AC or AT) and endocrine therapy.
Thursday, December 8, 2016
Session Number: Poster Session 2, P2-05-06
Session Title: Prognostic and Predictive Factors: Prognostic Factors – Clinical Testing and Validation.
Abstract Title: Analytical and clinical validation of a fully automated tissue-based quantitative assay MetaSite Breast™ to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC).
Authors: Michael J. Donovan, MD, PhD, Joan G. Jones, MD, David R.
Entenberg, MSc, John S. Condeelis, PhD, Timothy M. D'Alfonso, MD, Mark
Gustavson, PhD, Annette Molinaro, MA, PhD, Maja H. Oktay, MD, PhD,
Xiaonan Xue, PhD, Joseph A. Sparano, MD, Michael A. Peterson, BSc, Olga
Podznyakova, MD, PhD, Thomas E. Rohan, MBBS, PhD, Anthony P. Shuber,
MSc, Frank B. Gertler, PhD, Amy Ly, MD, Michelle E. Divelbiss, MSc,
Douglas A. Hamilton, BSc, MBA.
Location: Hall 1
Session Time: 7:30 a.m. - 9:00 a.m.
Program Number: S4-04
Oral Presentation in General Session 4: Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC).
Authors: Joseph A. Sparano, MD, Robert Gray, PhD, Maja H Oktay,
MD, PhD, David Entenberg, MS, Thomas Rohan, MBBS, PhD, Xioanan Xue, PhD,
Michael Donovan, MD, PhD, Michael Peterson, MD, Anthony Shuber, Douglas
Hamilton, BSc, MBA, Timothy D'Alfonso, MD, Lori J Goldstein, MD, Frank
Gerlter, PhD, Nancy Davidson, MD, John Condeelis, PhD, Joan Jones, MD.
Session Time: 3:15 p.m. - 5:00 p.m.
About MetaSite Breast™
The MetaSite Breast™ test is intended for use in patients with early stage (stage 1-3), invasive breast cancer who have node-negative or node positive (1-3), estrogen receptor-positive, HER2-negative disease. Clinical studies have demonstrated the MetaSite score (MS) is significantly associated with increased risk of cancer metastasis. MetaSite Breast™ is a fully automated immunohistochemistry-based assay performed on formalin-fixed paraffin-embedded (FFPE) tissue. Using proprietary digital pathology and image analysis methods, the assay identifies and quantifies the number of micro-anatomical structures called MetaSites, consisting of a Mena expressing cancer cell, an endothelial cell and a perivascular macrophage. MetaSites have been shown to be the portal of entry for cancer cells into the blood stream contributing to the development of cancer metastasis. The MetaSite Breast™ assay is analytically validated under CLIA and clinically available through MetaStat’s CLIA-certified commercial laboratory located in Boston, MA.
About MetaStat, Inc.
MetaStat, Inc. (MTST) develops and commercializes tissue-based diagnostic tests for prediction of cancer metastasis and companion diagnostics to predict drug response. MetaStat's driver-based diagnostic and therapeutic platform technology is based on the pivotal role of the Mena protein and its isoforms, a common pathway for the development of metastatic disease in epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on the aggressiveness of their tumor and risk the cancer will spread. MetaStat's testing platform improves treatment planning decisions by identifying patients at high-risk of metastasis who need aggressive therapy while sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. In addition, MetaStat’s diagnostics can identify patients most likely to benefit from specific treatments by predicting drug response based on the biology of their tumor. The company is based in Boston, MA.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.